NCT07179653View on ClinicalTrials.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

HBV Infection

Interventions

DRUG

TVAX-008

DRUG

Placebo

Trial Locations (1)

20000

NanFang Hospital, Guangzhou

All Listed Sponsors

collaborator

Nanfang Hospital, Southern Medical University

OTHER

collaborator

Sichuan Provincial People's Hospital

OTHER

collaborator

Meng Chao Hepatobiliary Hospital of Fujian Medical University

OTHER

collaborator

Ruijin Hospital

OTHER

lead

Grand Theravac Life Sciences (Nanjing) Co., Ltd.

INDUSTRY

NCT07179653 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients | Biotech Hunter | Biotech Hunter